Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Announcement of change in the total number of votes in AB SKF

Gothenburg, 26 February 2021: Due to a conversion of shares from Series A to Series B in accordance with AB SKF’s Articles of Association, the Company confirms the following. As per 26 February, the Company’s share capital amounts to SEK 1,138,377,670 and the total number of shares amounts to 31,319,602 shares of Series A and 424,031,466 shares of Series B. The number of votes in the Company amounts to 73,722,748.6. AB SKF does not hold any own shares. Aktiebolaget SKF      (publ) This is information that AB SKF is obliged to make public pursuant to the Financial Instruments

Sinch AB (publ): Change in number of shares and votes in Sinch AB (publ)

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH The total number of shares and votes in Sinch AB (publ), reg. no. 556882-8908 (“Sinch”), has changed during the month of February consequent upon the issue in-kind of 1,534,582 new shares to Movile International Holdings BV as a part of the purchase price for the acquisition of Wavy through the entities Movile Internet Móvel S.A. and Wavy Global Holdings BV, and the issue of 241,423 new shares upon exercise of warrants under the incentive programme adopted by the extraordinary general meeting held on December 5, 2016. Subsequent to the

Cline submits international patent application for StemCART therapy product

Cline Scientific (Spotlight Stock Market: CLINE B) today announces it has submitted an international PCT patent application covering methods related to the StemCART cartilage therapy project.This application is an extension to the patent application submitted to the European Patent Authority announced on the 28[th] of March 2020. “Our unique method and product have the potential to provide much-needed treatment to patients across the world. This is a vital step in fulfilling Cline’s strategy to gain strong protection for our groundbreaking stem-cell methods using our surface technology.”

Change in Management in Lagercrantz Group

The Board of Directors of Lagercrantz Group have appointed Jonas Ahlberg as Executive Vice President as of May 1[st] 2021. Jonas Ahlberg is Head of the growing division Niche Products and has worked within the Group since 2012. Magnus Söderlind (Executive Vice President) with responsibility for Business Development and M&A, will leave the Group as of April 30 2021. As announced via a Press Release from Bergman & Beving earlier today, Magnus will become President and CEO of Bergman & Beving AB (BERG-B) as of May 1[st] 2021. We thank Magnus for his time within Lagercrantz and wish him all

Mandatory Notification of Trade by Close Associate of Primary Insider

Ajea Invest AS, a company owned 100% by board member in Arctic Bioscience AS, Asbjørn Solevågseide, has on 25 February 2021 acquired 17,500 shares in Arctic Bioscience AS. The shares were acquired at Euronext Growth Oslo at a price of NOK 28,4405 per share. After this transaction, Ajea Invest AS holds 275,564 Shares in Arctic Bioscience AS directly, and 12.8% of the share capital in PIR IV Invest AS, which holds 2,188,250 Shares in the Company.

Nel ASA: Share capital increase registered

(Oslo, 26 February 2021) Reference is made to the stock exchange announcement by Nel ASA (the "Company") on 24 February 2021 regarding the issue of 49,500,000 new shares upon completion of a private placement of shares. The share capital increase pertaining to the issuance of the new shares under the private placement has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is NOK 291,459,497.60 divided on 1,457,297,488 shares, each with a nominal value of NOK 0.20 per share. ENDS For additional information, please

Beijer Ref acquires Coolair in Germany

Air conditioning is a prioritized growth area and Beijer Ref continues to increase its market share within the air conditioning (HVAC) sector. The growth strategy is further assisted through the acquisition of 60% of the shares in coolair Klimasysteme GmbH (Coolair) with the option to acquire the remaining shares.Coolair is headquartered in Nordhorn, Germany and sells air conditioning products from leading brands such as Toshiba, LG and Beijer Ref’s private label brand, Sinclair. Coolair’s annual sales amount to SEK 100 million with good profitability and over 25 employees. Both parties

Senzime’s Year-End Report 2020

Press release: Uppsala, February 26, 2021. Senzime AB’s (publ) Year-End Report for 2020 is now available on the company’s website www.senzime.com.· Breakthrough orders in the US, UK, France and Germany · Out-licensing of OnZurf® Probe in a deal worth more than SEK 100 million · Strengthened balance sheet through new share issues of SEK 170 million Financial information for the fourth quarter 2020 · Net sales amounts to KSEK 3,494 (2,688) · Income after financial items amounts to KSEK -15,570 (-9,616) · Earnings per share amounts to SEK -0.26 (-0.18) · Cash and cash

Cygate selects Cinode for more efficient Skills Management

Cygate and Telia Professional Services implements Cinode to manage competence, CVs and matching of requested skills with available employees.- Cinode will make it significantly easier for us to find the right skills and streamline staffing. We are also increasing the possibility of staffing between units and geographies, shortening the sales cycle for consultants and improving our forecasts, says Fredrik Sidmar, CEO of Cygate and Head of Telia Professional Services. Today, organizations lack internal structure and knowledge to manage their most important asset - employee competence. The

BioStock: Ultimovacs Begins Clinical Evaluation of Novel TET-Platform

After presenting their 2020 Q4 report, Ultimovacs immediately turned their attention back to 2021 by announcing the initiation of a new phase I study, TENDU. The TENDU trial is aimed at testing the company’s TET-platform in prostate cancer patients. The platform is based on innovative patented technology that has the potential to generate multiple cancer vaccine candidates.Read the full article at biostock.se: https://www.biostock.se/2021/02/ultimovacs-paborjar-klinisk-evaluering-av-ny-tet-platform/   This is a press release from BioStock - Connecting Innovation & Capital.

Nordic Mining ASA: New share capital registered

Reference is made to the stock exchange release from Nordic Mining ASA ("Nordic Mining" or the "Company") published 24 February 2021 regarding the completion of the Private Placement. The Private Placement consisted of 32,000,000 new shares at a subscription price of NOK 2.50 per share, each with a par value of NOK 0.60. The share capital increase has been registered with the Norwegian Register of Business Enterprises today. Following registration of the new share capital Nordic Mining’s share capital has increased by NOK 19,200,000 to NOK 137,695,063.20 divided into 229,491,772

Contract awards in Australia

Solstad Offshore ASA (“Solstad”) is pleased to confirm that the large AHTS Normand Ranger has been awarded a contract in Australia for commencement in 2Q 2021. The vessel will mobilise from Norway and will then provide support to a major drilling campaign offshore North Western Australia, securing about 1 year of utilization for the vessel. During the drilling campaign, that also includes support from the Solstad AHTSs Normand Saracen and Far Senator, the Normand Ranger will operate in connection with a moored semi-submersible drilling rig, with the base port being Dampier. In

Salmon Evolution executes on Asia growth strategy – establishes joint venture with seafood giant Dongwon Industries

Molde/Ålesund/Seoul, 26 February 2021: Salmon Evolution Holding AS (“Salmon Evolution” or the “Company”, OSE: SALME) – a leading land-based salmon farming business with its first production facility under construction at Indre Harøy in western Norway – is pleased to inform that the company today has signed a Joint Venture Term Sheet with Dongwon Industries, a leading seafood company based in South Korea, for the establishment of a 49/51 joint venture, to be named K Smart Farming (“K Smart”).  Key highlights: · 20,000 tons LWE production facility in South Korea using Salmon Evolution’

Invitation to Asetek's Capital Markets Update on Thursday 4 March

February 26, 2021 - Asetek is pleased to invite investors, analysts, media and other stakeholders to its Capital Markets Update (CMU) and Q4 2020 earnings presentation on Thursday 4 March 2021. The CMU presentation will be given in English by CEO André Sloth Eriksen, COO John Hamill, CFO Peter Dam Madsen and VP & General Manager Jim Carlton, and will be published as a webcast with accompanying slides. The CMU will provide an update on Asetek’s strategy, markets, operations, financial development and outlook. Asetek’s recent investments in IP, software and hardware as part of

Q2 - Interim Report October 2020 – December 2020

Opening remarks The second quarter of this fiscal year has been very productive for Hamlet Pharma. The clinical trials program has continued and in January, the first patient was included.  The patients will receive increased doses of Alpha1H or combination therapy with Alpha1H and low doses of Epirubicin, an established bladder cancer drug. Information from this study program will be essential for the design of Phase III trials. Despite the COVID-19 pandemic, the team in Prague is very motivated and drives the clinical activities forward to develop Alpha1H towards a new drug for patients

Interim Financial Report

January – December 2020 Despite the significant challenges related to Covid-19, including a revenue drop of nearly 45% experienced in Q2, our second half revenue rebounded to pre pandemic levels. Solid recovery in Commercial Vehicle markets and maturation of key Passenger Car programs spearheaded the improvement. Q4 revenue coming in at 463.3 MSEK was particularly encouraging. 2020 Full year performance improved by 160 basis points in adjusted EBITDA margin coming in at 8.2% versus 6.8% adjusted EBITDA margin in 2019. This improvement comes despite Q2 2020 margin at (-0.4%) versus 6.7%

YEAR END REPORT Period from January 2020 to December 2020

Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED) Group, Lune Group OY incl subsidiary is included from 2020-06-03 2020 FOURTH QUARTER (Oct-Dec) · Net sales of products KSEK 7,258 (394) · Gross profit KSEK 3,866 (321), Gross margin 53% (81%) · Operating loss KSEK -10,702 (-11,508)  · Loss per share SEK -0.07 (-0.08) FULL YEAR 2020 (Jan-Dec) · Net sales of products KSEK 21,283 (4,408) · Gross profit KSEK 13,089 (2,583), Gross margin 61% (59%) ·

MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2020

Promising clinical results, successful business development and secured financingOctober – DecemberFinancial summary for the quarter · Net turnover amounted to SEK 1.5 (1.4) million. · The profit before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -10.6(-30.3) million. Basic and diluted earnings per share amounted to SEK -0.46 (-1.32) and SEK -0.46 (-1.32) respectively. · Cash flow from operating activities amounted to SEK -1.0 (-23.6) million. · Liquid assets and short-term investments at the end of the period amounted to SEK 70.0 (134.5) million.

Interim Financial Report – full year of 2020 (incl. Q4 2020)

Q4 of 2020 consolidated financial statements describe the operating results of SGL TransGroup International A/S (SGL Group). · The Q4 2020 revenue was DKK 1,492 million, the full year of 2020 revenue was DKK 5,351 million and increased by 29% vs the full year of 2019. · The Q4 2020 Gross Profit was DKK 249 million, the full year of 2020 Gross Profit was DKK 955 million and the Gross Margin equals 17.8%. · The Q4 2020 EBITDA before special items excl. IFRS 16 amounts to DKK 53 million, the full year of 2020 EBITDA before special items excl. IFRS 16 was DKK 237 million; equal to an

Invitation to the webcast on Fortum's Financial Statements Bulletin 2020

FORTUM CORPORATION INVESTOR NEWS 26 FEBRUARY 2021 AT 9:30 EET Fortum's Financial Statements Bulletin 2020 will be published on 12 March 2021 at approximately 9:00 EET. A combined live webcast/teleconference for media, investors, and analysts will be arranged online on the same day at 11:00 EET. For the webcast, use the link on www.fortum.com/investors. To participate in the teleconference and Q&A, dial in using the numbers below: FI: +358 9 817 10310UK: +44 333 300 0804US: +1 631 913 1422 PIN: 43874018# A recording of the webcast as well as the transcript will be

Year-End Report Nanologica 2020

SUMMARY OF THE PERIODFINANCIAL OVERVIEW · Net revenue increased by 75 percent to TSEK 16 135 (9 227) in total, of which the fourth quarter TSEK 6 071 (2 731) · The operating result for the period was TSEK -19 571 (-20 066), of which the fourth quarter TSEK -3 648 (-6 260) · Loss for the period was TSEK -22 199 (-21 080), of which the fourth quarter TSEK -5 427 (-6 855) · Loss per share for the period was SEK -0,93 (-1,27), of which the fourth quarter SEK -0,20 (-0,41) · Cash and cash equivalents at the end of the period amounted to TSEK  66 364 (1 176) SIGNIFICANT EVENTS

Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article

As previously communicated in December 2020, results from the investigator-initiated phase II study performed by researchers at Rigshospitalet were available in 2020. Now, these results are published in the March 2021 issue of the Journal of Nuclear Medicine, which is the most recognized scientific journal in the field of nuclear medicine (highest impact factor). Furthermore, the article (available here)  has been selected as Featured Clinical Investigation Article of the March issue.The phase II study The phase II study aimed to evaluate the

Change in Number of Shares in Nanologica AB

The number of shares in Nanologica AB (publ) has changed during the month of February as a result of options from the stock option program 2018/21 being exercised.A share-based incentive program of a maximum of 483 883 options was decided by the Annual General Meeting May 31, 2018. The program expires July 1st, 2021 and the options may be exercised any time before that to a strike price of SEK 9.3. According to the Financial Instruments Trading Act (1991:980), any changes in the total number of shares in Swedish publicly traded companies shall be made public per the last day of trade of the

Kamux’s transfer of own shares for payment of share-based incentives 2020

Kamux Corporation    Stock Exchange Release    26 February 2021 at 9:10 (EET) Kamux’s transfer of own shares for payment of share-based incentives 2020 The Board of Directors of Kamux Corporation (“Company”) has confirmed the remuneration to be paid to the key personnel of the Kamux Group in accordance with the terms and conditions of the share-based incentive scheme and the earnings criteria set for the year 2020. According to the terms and conditions of the share-based incentive scheme 2020 and after the deduction of the cash payment portions of the remunerations meant for taxes and

There are no items matching the current filter
There are no more items matching the current filter
Back to top